Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QHL-1031
- Development stage
- Preclinical
- Lead developer
- Affinity Biopharmaceutical
- Modality
- Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
QHL-1031 is a small molecule drug conjugate (SMDC) that functions as a Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8) agonist. Developed by Shanghai Affinity Biopharmaceutical using its proprietary Tumor MicroEnvironment Activated (TMEA) platform, the drug is designed to selectively activate the innate immune system within the tumor microenvironment. By stimulating TLR7 and TLR8, QHL-1031 promotes the release of pro-inflammatory cytokines and the activation of antigen-presenting cells, such as dendritic cells and macrophages, to mount an effective anti-tumor response while minimizing systemic toxicity. It is currently in the IND-enabling/pre-clinical stage for the treatment of various solid tumors.
02
Targets
TLR7 (Toll-like receptor 7)TLR8 (Toll-like receptor 8)
Beyond the preview
Go deeper on QHL-1031.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QHL-1031.